Radiopharmaceutical developer Navidea Biopharmaceuticals has received a $321,000 grant from the U.S. National Institutes of Health's (NIH) National Heart, Lung, and Blood Institute.
The grant will be used to conduct a study in collaboration with Massachusetts General Hospital and Harvard Medical School that will examine the effectiveness of Navidea's technetium-99m (Tc-99m) tilmanocept in identifying cardiovascular disease, Navidea said. Tc-99m tilmanocept is part of the company's Manocept group of agents.
